Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company's Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer's executive leadership team as executive vice president and chief medical officer, as well as leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation and Eli Lilly and Company. A Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, she will provide scientific, clinical and regulatory governance across Helus' portfolio as the company advances its novel serotonergic agonist programs targeting serious mental health conditions.
The appointment comes at a critical time for Helus Pharma, which is developing proprietary NSAs – novel serotonergic agonists – designed to activate serotonin pathways believed to promote neuroplasticity. The company is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. Dr. Lewis-Hall's expertise is expected to be instrumental in guiding these programs through clinical development and regulatory processes.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing synthetic molecules intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma is a trademark of Cybin Corp.
NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
